The interferon-stimulated gene IFITM3 restricts infection and pathogenesis of arthritogenic and encephalitic alphaviruses

Journal of Virology

Volumn 90, Issue 19, 2016, Pages 8780-8794

  Poddar, Subhajit ^a   Hyde, Jennifer L ^a   Gorman, Matthew J ^a   Farzan, Michael ^b   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EOTAXIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR; CYTOKINE; FRAGILIS PROTEIN, MOUSE; IMMUNOLOGIC FACTOR; MEMBRANE PROTEIN;

ALPHAVIRUS INFECTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE ARTHRITIS; ANTIVIRAL ACTIVITY; ARTICLE; CHIKUNGUNYA; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION; IFITM3 GENE; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; VIRUS ATTACHMENT; VIRUS ENCEPHALITIS; VIRUS ENTRY; VIRUS GENE; VIRUS LOAD; VIRUS REPLICATION; VIRUS TITRATION; VIRUS VIRULENCE; ANIMAL; CHIKUNGUNYA VIRUS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; FIBROBLAST; GENE DELETION; GENETIC COMPLEMENTATION; IMMUNOLOGY; KNOCKOUT MOUSE; MACROPHAGE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SECRETION (PROCESS); VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VIROLOGY;

ALPHAVIRUS INFECTIONS; ANIMALS; CHIKUNGUNYA VIRUS; CYTOKINES; DISEASE MODELS, ANIMAL; ENCEPHALITIS VIRUS, VENEZUELAN EQUINE; FIBROBLASTS; GENE DELETION; GENETIC COMPLEMENTATION TEST; IMMUNOLOGIC FACTORS; MACROPHAGES; MEMBRANE PROTEINS; MICE; MICE, KNOCKOUT; VIRAL LOAD; VIRUS INTERNALIZATION;

EID: 84990202526     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00655-16     Document Type: Article

References (73)

1. Diamond MS, Farzan M. 2013. The broad-spectrum antiviral functions of IFIT and IFITM proteins. Nat Rev Immunol 13:46-57. http://dx.doi.org/10.1038/nri3344
2. Friedman RL, Manly SP, McMahon M, Kerr IM, Stark GF. 1984. Transcriptional and posttranscriptional regulation of interferon-induced gene expression in human cells. Cell 38:745-755
3. Siegrist F, Ebeling M, Certa U. 2011. The small interferon-induced transmembrane genes and proteins. J Interferon Cytokine Res 31:183-197. http://dx.doi.org/10.1089/jir.2010.0112
4. Chesarino NM, McMichael TM, Yount JS. 2014. Regulation of the trafficking and antiviral activity of IFITM3 by post-translational modifications. Future Microbiol 9:1151-1163. http://dx.doi.org/10.2217/fmb.14.65
5. Smith R, Young J, Weis JJ, Weis JH. 2006. Expression of the mouse fragilis gene products in immune cells and association with receptor signaling complexes. Genes Immun 7:113-121. http://dx.doi.org/10.1038/sj.gene.6364278
6. Ling S, Zhang C, Wang W, Cai X, Yu L, Wu F, Zhang L, Tian C. 2016. Combined approaches of EPR and NMR illustrate only one transmembrane helix in the human IFITM3. Sci Rep 6:24029. http://dx.doi.org/10.1038/srep24029
7. Brass AL, Huang I-C, Benita Y, John SP, Krishnan MN, Feeley EM, Ryan BJ, Weyer JL, Van Der Weyden L, Fikrig E, Adams J, Xavier RJ, Farzan M, Elledge SJ. 2009. The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus. Cell 139:1243-1254. http://dx.doi.org/10.1016/j.cell.2009.12.017
8. Mudhasani R, Tran JP, Retterer C, Radoshitzky SR, Kota KP, Altamura LA, Smith JM, Packard BZ, Kuhn JH, Costantino J, Garrison AR, Schmaljohn CS, Huang I-C, Farzan M, Bavari S. 2013. IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus. J Virol 87:8451-8464. http://dx.doi.org/10.1128/JVI.03382-12
9. Huang I-C, Bailey CC, Weyer JL, Radoshitzky SR, Becker MM, Chiang JJ, Brass AL, Ahmed AA, Chi X, Dong L, Longobardi LE, Boltz D, Kuhn JH, Elledge SJ, Bavari S, Denison MR, Choe H, Farzan M. 2011. Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog 7:e1001258. http://dx.doi.org/10.1371/journal.ppat.1001258
10. Lu J, Pan Q, Rong L, He W, Liu SL, Liang C. 2011. The IFITM proteins inhibit HIV-1 infection. J Virol 85:2126-2137. http://dx.doi.org/10.1128/JVI.01531-10
11. Everitt AR, Clare S, McDonald JU, Kane L, Harcourt K, Ahras M, Lall A, Hale C, Rodgers A, Young DB, Haque A, Billker O, Tregoning JS, Dougan G, Kellam P. 2013. Defining the range of pathogens susceptible to Ifitm3 restriction using a knockout mouse model. PLoS One 8:e80723. http://dx.doi.org/10.1371/journal.pone.0080723
12. Perreira JM, Chin CR, Feeley EM, Brass AL. 2013. IFITMs restrict the replication of multiple pathogenic viruses. J Mol Biol 425:4937-4955. http://dx.doi.org/10.1016/j.jmb.2013.09.024
13. Chan YK, Huang I-C, Farzan M. 2012. IFITM proteins restrict antibodydependent enhancement of dengue virus infection. PLoS One 7:e34508. http://dx.doi.org/10.1371/journal.pone.0034508
14. Chutiwitoonchai N, Hiyoshi M, Hiyoshi-Yoshidomi Y, Hashimoto M, Tokunaga K, Suzu S. 2013. Characteristics of IFITM, the newly identified IFN-inducible anti-HIV-1 family proteins. Microbes Infect 15:280-290. http://dx.doi.org/10.1016/j.micinf.2012.12.003
15. Anafu A, Bowen CH, Chin CR, Brass AL, Holm GH. 2013. Interferoninducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry. J Biol Chem 288:17261-17271. http://dx.doi.org/10.1074/jbc. M112.438515
16. Jiang D, Weidner JM, Qing M, Pan X-B, Guo H, Xu C, Zhang X, Birk A, Chang J, Shi P-Y, Block TM, Guo J-T. 2010. Identification of five interferon-induced cellular proteins that inhibit West Nile virus and dengue virus infections. J Virol 84:8332-8341. http://dx.doi.org/10.1128/JVI.02199-09
17. Narayana SK, Helbig KJ, McCartney EM, Eyre NS, Bull RA, Eltahla A, Lloyd AR, Beard MR. 2015. The interferon-induced transmembrane proteins, IFITM1, IFITM2, and IFITM3 inhibit hepatitis C virus entry. J Biol Chem 290:25946-25959. http://dx.doi.org/10.1074/jbc. M115.657346
18. Bailey CC, Huang I-C, Kam C, Farzan M. 2012. Ifitm3 limits the severity of acute influenza in mice. PLoS Pathog 8:e1002909. http://dx.doi.org/10.1371/journal.ppat.1002909
19. Everitt AR, Clare S, Pertel T, John SP, Wash RS, Smith SE, Chin CR, Feeley EM, Sims JS, Adams DJ, Wise HM, Kane L, Goulding D, Digard P, Anttila V, Baillie JK, Walsh TS, Hume DA, Palotie A, Xue Y, Colonna V, Tyler-Smith C, Dunning J, Gordon SB, Smyth RL, Openshaw PJ, Dougan G, Brass AL, Kellam P. 2012. IFITM3 restricts the morbidity and mortality associated with influenza. Nature 484:519-523. http://dx.doi.org/10.1038/nature10921
20. Zhang Y-H, Zhao Y, Li N, Peng Y-C, Giannoulatou E, Jin R-H, Yan H-P, Wu H, Liu J-H, Liu N, Wang D-Y, Shu Y-L, Ho L-P, Kellam P, McMichael A, Dong T. 2013. Interferon-induced transmembrane protein-3 genetic variant rs12252-C is associated with severe influenza in Chinese individuals. Nat Commun 4:1418. http://dx.doi.org/10.1038/ncomms2433
21. Wang Z, Zhang A, Wan Y, Liu X, Qiu C, Xi X, Ren Y, Wang J, Dong Y, Bao M, Li L, Zhou M, Yuan S, Sun J, Zhu Z, Chen L, Li Q, Zhang Z, Zhang X, Lu S, Doherty PC, Kedzierska K, Xu J. 2014. Early hypercytokinemia is associated with interferon-induced transmembrane protein-3 dysfunction and predictive of fatal H7N9 infection. Proc Natl Acad Sci U S A 111:769-774. http://dx.doi.org/10.1073/pnas.1321748111
22. Williams DEJ, Wu W-L, Grotefend CR, Radic V, Chung C, Chung Y-H, Farzan M, Huang I-C. 2014. IFITM3 polymorphism rs12252-C restricts influenza A viruses. PLoS One 9:e110096. http://dx.doi.org/10.1371/journal.pone.0110096
23. Weidner JM, Jiang D, Pan X-B, Chang J, Block TM, Guo J-T. 2010. Interferon-induced cell membrane proteins, IFITM3 and tetherin, inhibit vesicular stomatitis virus infection via distinct mechanisms. J Virol 84: 12646-12657. http://dx.doi.org/10.1128/JVI.01328-10
24. Desai TM, Marin M, Chin CR, Savidis G, Brass AL, Melikyan GB. 2014. IFITM3 restricts influenza A virus entry by blocking the formation of fusion pores following virus-endosome hemifusion. PLoS Pathog 10: e1004048. http://dx.doi.org/10.1371/journal.ppat.1004048
25. Feeley EM, Sims JS, John SP, Chin CR, Pertel T, Chen L-M, Gaiha GD, Ryan BJ, Donis RO, Elledge SJ, Brass AL. 2011. IFITM3 inhibits influenza A virus infection by preventing cytosolic entry. PLoS Pathog 7:e1002337. http://dx.doi.org/10.1371/journal.ppat.1002337
26. Li K, Markosyan RM, Zheng Y-M, Golfetto O, Bungart B, Li M, Ding S, He Y, Liang C, Lee JC, Gratton E, Cohen FS, Liu S-L. 2013. IFITM proteins restrict viral membrane hemifusion. PLoS Pathog 9:e1003124. http://dx.doi.org/10.1371/journal.ppat.1003124
27. Compton AA, Bruel T, Porrot F, Mallet A, Sachse M, Euvrard M, Liang C, Casartelli N, Schwartz O. 2014. IFITM proteins incorporated into HIV-1 virions impair viral fusion and spread. Cell Host Microbe 16:736-747. http://dx.doi.org/10.1016/j.chom.2014.11.001
28. Bailey CC, Zhong G, Huang I-C, Farzan M. 2014. IFITM-family proteins: the cell's first line of antiviral defense. Annu Rev Virol 1:261-283. http://dx.doi.org/10.1146/annurev-virology-031413-085537
29. Lin T-Y, Chin CR, Everitt AR, Clare S, Perreira JM, Savidis G, Aker AM, John SP, Sarlah D, Carreira EM, Elledge SJ, Kellam P, Brass AL. 2013. Amphotericin B increases influenza A virus infection by preventing IFITM3-mediated restriction. Cell Rep 5:895-908. http://dx.doi.org/10.1016/j.celrep.2013.10.033
30. Lescar J, Roussel A, Wien MW, Navaza J, Fuller SD, Wengler G, Wengler G, Rey FA. 2001. The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 105:137-148. http://dx.doi.org/10.1016/S0092-8674(01)00303-8
31. Smith TJ, Cheng RH, Olson NH, Peterson P, Chase E, Kuhn RJ, Baker TS. 1995. Putative receptor binding sites on alphaviruses as visualized by cryoelectron microscopy. Proc Natl Acad SciUS A 92:10648-10652. http://dx.doi.org/10.1073/pnas.92.23.10648
32. Cheng RH, Kuhn RJ, Olson NH, Rossmann MG, Choi HK, Smith TJ, Baker TS. 1995. Nucleocapsid and glycoprotein organization in an enveloped virus. Cell 80:621-630. http://dx.doi.org/10.1016/0092-8674(95)90516-2
33. Petersen LR, Powers AM. 2016. Chikungunya: epidemiology. F1000Res 5:82. http://dx.doi.org/10.12688/f1000research.7171.1
34. Steele KE, Twenhafel N. 2010. Review paper: pathology of animal models of alphavirus encephalitis. Vet Pathol 47:790-805. http://dx.doi.org/10.1177/0300985810372508
35. Caglioti C, Lalle E, Castilletti C, Carletti F, Capobianchi MR, Bordi L. 2013. Chikungunya virus infection: an overview. New Microbiol 36:211-227
36. Morrison TE, Oko L, Montgomery SA, Whitmore AC, Lotstein AR, Gunn BM, Elmore SA, Heise MT. 2011. A mouse model of chikungunya virus-induced musculoskeletal inflammatory disease: evidence of arthritis, tenosynovitis, myositis, and persistence. Am J Pathol 178:32-40. http://dx.doi.org/10.1016/j.ajpath.2010.11.018
37. Couderc T, Chrétien F, Schilte C, Disson O, Brigitte M, Guivel-Benhassine F, Touret Y, Barau G, Cayet N, Schuffenecker I, Desprès P, Arenzana-Seisdedos F, Michault A, Albert ML, Lecuit M. 2008. A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 4:e29. http://dx.doi.org/10.1371/journal.ppat.0040029
38. Chen W, Foo S-S, Rulli NE, Taylor A, Sheng K-C, Herrero LJ, Herring BL, Lidbury B, Li RW, Walsh NC, Sims N, Smith PN, Mahalingam S. 2014. Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss. Proc Natl Acad Sci U S A 111:6040-6045. http://dx.doi.org/10.1073/pnas.1318859111
39. Chen W, Foo SS, Sims NA, Herrero LJ, Walsh NC, Mahalingam S. 2015. Arthritogenic alphaviruses: new insights into arthritis and bone pathology. Trends Microbiol 23:35-43. http://dx.doi.org/10.1016/j.tim.2014.09.005
40. Lenschow DJ, Giannakopoulos NV, Gunn LJ, Johnston C, O'Guin AK, Schmidt RE, Levine B, Virgin HW. 2005. Identification of interferonstimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 79:13974-13983. http://dx.doi.org/10.1128/JVI.79.22.13974-13983.2005
41. Lenschow DJ, Lai C, Frias-Staheli N, Giannakopoulos NV, Lutz A, WolffT, Osiak A, Levine B, Schmidt RE, García-Sastre A, Leib DA, Pekosz A, Knobeloch K, Horak I, Virgin HW. 2007. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A 104:1371-1376. http://dx.doi.org/10.1073/pnas.0607038104
42. Werneke SW, Schilte C, Rohatgi A, Monte KJ, Michault A, Arenzana-Seisdedos F, Vanlandingham DL, Higgs S, Fontanet A, Albert ML, Lenschow DJ. 2011. ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation. PLoS Pathog 7:e1002322. http://dx.doi.org/10.1371/journal.ppat.1002322
43. Jones PH, Maric M, Madison MN, Maury W, Roller RJ, Okeoma CM. 2013. BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1). Virology 438:37-49. http://dx.doi.org/10.1016/j.virol.2013.01.010
44. Ryman KD, Meier KC, Nangle EM, Ragsdale SL, Korneeva NL, Rhoads RE, Macdonald MR, Klimstra WB. 2005. Sindbis virus translation is inhibited by a PKR/RNase L-independent effector induced by alpha/beta interferon priming of dendritic cells. J Virol 79:1487-1499. http://dx.doi.org/10.1128/JVI.79.3.1487-1499.2005
45. Zhang Y, Burke CW, Ryman KD, Klimstra WB. 2007. Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. J Virol 81:11246-11255. http://dx.doi.org/10.1128/JVI.01282-07
46. Hyde JL, Gardner CL, Kimura T, White JP, Liu G, Trobaugh DW, Huang C, Tonelli M, Paessler S, Takeda K, Klimstra WB, Amarasinghe GK, Diamond MS. 2014. A viral RNA structural element alters host recognition of nonself RNA. Science 343:783-787. http://dx.doi.org/10.1126/science.1248465
47. Weston S, Czieso S, White IJ, Smith SE, Wash RS, Diaz-Soria C, Kellam P, Marsh M. 24 May 2016. Alphavirus restriction by IFITM proteins. Traffic http://dx.doi.org/10.1111/tra.12416
48. Schoggins JW, Rice CM. 2011. Interferon-stimulated genes and their antiviral effector functions. Curr Opin Virol 1:519-525. http://dx.doi.org/10.1016/j.coviro.2011.10.008
49. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485. http://dx.doi.org/10.1038/nature09907
50. Karki S, Li MM, Schoggins JW, Tian S, Rice CM, Macdonald MR. 2012. Multiple interferon stimulated genes synergize with the zinc finger antiviral protein to mediate anti-alphavirus activity. PLoS One 7:e37398. http://dx.doi.org/10.1371/journal.pone.0037398
51. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC
52. Lange UC, Adams DJ, Lee C, Barton S, Schneider R, Bradley A, Surani MA. 2008. Normal germ line establishment in mice carrying a deletion of the Ifitm/Fragilis gene family cluster. Mol Cell Biol 28:4688-4696. http://dx.doi.org/10.1128/MCB.00272-08
53. Wakeland E, Morel L, Achey K, Yui M, Longmate J. 1997. Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol Today 18: 472-477. http://dx.doi.org/10.1016/S0167-5699(97)01126-2
54. Pal P, Dowd KA, Brien JD, Edeling MA, Gorlatov S, Johnson S, Lee I, Akahata W, Nabel GJ, Richter MKS, Smit JM, Fremont DH, Pierson TC, Heise MT, Diamond MS. 2013. Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus. PLoS Pathog 9:e1003312. http://dx.doi.org/10.1371/journal.ppat.1003312
55. Oliphant T, Engle M, Nybakken GE, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung KM, Ebel GD, Kramer LD, Fremont DH, Diamond MS. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11:522-530. http://dx.doi.org/10.1038/nm1240
56. Oliphant T, Nybakken GE, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi B-E, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. 2006. Antibody recognition and neutralization determinants on domains I and II of West Nile virus envelope protein. J Virol 80:12149-12159. http://dx.doi.org/10.1128/JVI.01732-06
57. Lazear HM, Pinto AK, Vogt MR, Gale M, Diamond MS. 2011. Beta interferon controls West Nile virus infection and pathogenesis in mice. J Virol 85:7186-7194. http://dx.doi.org/10.1128/JVI.00396-11
58. Dora S, Schwarz C, Baack M, Graessmann A, Knippers R. 1989. Analysis of a large-T-antigen variant expressed in simian virus 40-transformed mouse cell line mKS-A. J Virol 63:2820-2828
59. Araki T, Sasaki Y, Milbrandt J. 2004. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305:1010-1013. http://dx.doi.org/10.1126/science.1098014
60. Cho H, Proll SC, Szretter KJ, Katze MG, Gale M, Diamond MS. 2013. Differential innate immune response programs in neuronal subtypes determine susceptibility to infection in the brain by positive-stranded RNA viruses. Nat Med 19:1-8. http://dx.doi.org/10.1038/nm.3061
61. Tsetsarkin K, Higgs S, McGee CE, De Lamballerie X, Charrel RN, Vanlandingham DL. 2006. Infectious clones of Chikungunya virus (La Réunion isolate) for vector competence studies. Vector Borne Zoonotic Dis 6:325-337. http://dx.doi.org/10.1089/vbz.2006.6.325
62. Morrison TE, Whitmore AC, Shabman RS, Lidbury BA, Mahalingam S, Heise MT. 2006. Characterization of Ross River virus tropism and virus-induced inflammation in a mouse model of viral arthritis and myositis. J Virol 80:737-749. http://dx.doi.org/10.1128/JVI.80.2.737-749.2006
63. Smith SA, Silva LA, Fox JM, Flyak AI, Kose N, Sapparapu G, Khomandiak S, Ashbrook AW, Kahle KM, Fong RH, Swayne S, Doranz BJ, McGee CE, Heise MT, Pal P, Brien JD, Austin SK, Diamond MS, Dermody TS, Crowe JE. 2015. Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against chikungunya virus. Cell Host Microbe 18:86-95. http://dx.doi.org/10.1016/j.chom.2015.06.009
64. Wahlberg JM, GaroffH. 1992. Membrane fusion process of Semliki Forest virus. I: Low pH-induced rearrangement in spike protein quaternary structure precedes virus penetration into cells. J Cell Biol 116: 339-348
65. Bailey CC, Kondur HR, Huang I-C, Farzan M. 2013. Interferon-induced transmembrane protein 3 is a type II transmembrane protein. J Biol Chem 288:32184-32193. http://dx.doi.org/10.1074/jbc. M113.514356
66. Amini-Bavil-Olyaee S, Choi YJ, Lee JH, Shi M, Huang I-C, Farzan M, Jung JU. 2013. The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry. Cell Host Microbe 13:452-464. http://dx.doi.org/10.1016/j.chom.2013.03.006
67. Edwards J, Brown DT. 1986. Sindbis virus-mediated cell fusion from without is a two-step event. J Gen Virol 67:377-380. http://dx.doi.org/10.1099/0022-1317-67-2-377
68. Hawman DW, Stoermer K, Montgomery S, Pal P, Oko L, Diamond MS, Morrison TE. 2013. Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response. J Virol 87:13878-13888. http://dx.doi.org/10.1128/JVI.02666-13
69. Fros JJ, Major LD, Scholte FEM, Gardner J, Van Hemert MJ, Suhrbier A, Pijlman GP. 2015. Chikungunya virus non-structural protein 2-mediated host shut-offdisables the unfolded protein response. J Gen Virol 96:580-589. http://dx.doi.org/10.1099/vir.0.071845-0
70. Hollidge BS, Weiss SR, Soldan SS. 2011. The role of interferon antagonist, non-structural proteins in the pathogenesis and emergence of arboviruses. Viruses 3:629-658. http://dx.doi.org/10.3390/v3060629
71. Schoggins JW, MacDuffDA, Imanaka N, Gainey MD, Shrestha B, Eitson JL, Mar KB, Richardson RB, Ratushny AV, Litvak V, Dabelic R, Manicassamy B, Aitchison JD, Aderem A, Elliott RM, García-Sastre A, Racaniello V, Snijder EJ, Yokoyama WM, Diamond MS, Virgin HW, Rice CM. 2014. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 505:691-695. http://dx.doi.org/10.1038/nature12862
72. Bick MJ, Carroll JN, Gao G, GoffSP, Rice CM, MacDonald MR. 2003. Expression of the zinc-finger antiviral protein inhibits alphavirus replication. J Virol 77:11555-11562. http://dx.doi.org/10.1128/JVI.77.21.11555-11562.2003
73. Gorman MJ, Poddar S, Farzan M, Diamond MS. 2016. The interferonstimulated gene IFITM3 restricts West Nile virus infection and pathogenesis. J Virol 90:8212-8225. http://dx.doi.org/10.1128/JVI.00581-16